Stem cell therapies for Type 1 diabetes: current status and proposed road map to guide successful clinical trials

2018 ◽  
Vol 36 (3) ◽  
pp. 297-307 ◽  
Author(s):  
P. A. Senior ◽  
J. H. Pettus
Keyword(s):  
Clinical Trials ◽  
Type 1 Diabetes ◽  
Stem Cell ◽  
Current Status ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Road Map

scholarly journals Latest Therapies for Type 1 Diabetes: Exsisting Setup and “Post-Insulin” Standpoints

2020 ◽  
Author(s):  
AMMIRA-SARAH AL-SHABEEB AKIL ◽  
Aljazi Al-Maraghi ◽  
ESRAA YASSIN ◽  
KHULOD AL-MALKI ◽  
KHALID FAKHRO
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Standard Of Care ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Long Acting ◽  
Near Future ◽  
Careful Management

Type 1 diabetes affects millions of people globally and requires careful management to avoid serious long-term complications, including heart and kidney disease, stroke, and loss of sight. The present standard-of-care for type 1 diabetes is exogenic insulin substitutional therapy. The most advanced stretegies in this area is the development of hybrid-closed loop system and the producing of long-acting insulins. Progresses in stem cell therapies have started to revolutionize the care of patients with type 1 diabetes; however, significant challenges remain including the limited islets availability, difficulties in maintaining the viability, the heterogeneity within a complex pathology and in patients’ responses to treatment. On the way, a considerable amount of efforts in maximizing the islet transplantation effectiveness by controlling the advantageous of different stem cell approaches. With the availability and the use of big data, the concept of precision medicine is gaining wide attention worldwide and could bring the dream of “presonlaized” therapies as a reality in the near future. Here we review the current range of treatments available as well as recent pre-clinical breakthroughs in the field of personlaized medicine for type 1 diabetes.

Feasibility of Induced Pluripotent Stem Cell Therapies for Treatment of Type 1 Diabetes

2018 ◽  
Vol 24 (6) ◽  
pp. 482-492
Author(s):  
Caden Duffy ◽  
Cesar Prugue ◽  
Rachel Glew ◽  
Taryn Smith ◽  
Calvin Howell ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Pluripotent Stem Cell ◽  
Induced Pluripotent Stem Cell ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Induced Pluripotent

scholarly journals Stem cell therapies for ischemic stroke: current animal models, clinical trials and biomaterials

RSC Advances ◽  
2017 ◽  
Vol 7 (30) ◽  
pp. 18668-18680 ◽  
Author(s):  
Hugh H. Chan ◽  
Connor A. Wathen ◽  
Ming Ni ◽  
Shuangmu Zhuo
Keyword(s):  
Tissue Engineering ◽  
Clinical Trials ◽  
Stem Cell ◽  
Ischemic Stroke ◽  
Animal Models ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Stem Cell Therapies ◽  
Cell Therapies

We report the facilitation of stem cell therapy in stroke by tissue engineering and applications of biomaterials.

scholarly journals Stem Cell Therapies in Clinical Trials: Workshop on Best Practices and the Need for Harmonization

2010 ◽  
Vol 7 (4) ◽  
pp. 451-454 ◽  
Author(s):  
Karen Martell ◽  
Alan Trounson ◽  
Elona Baum
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Best Practices ◽  
Stem Cell Therapies ◽  
Cell Therapies

scholarly journals Combating Osteoarthritis through Stem Cell Therapies by Rejuvenating Cartilage: A Review

2018 ◽  
Vol 2018 ◽  
pp. 1-13 ◽  
Author(s):  
Navneet Kumar Dubey ◽  
Viraj Krishna Mishra ◽  
Rajni Dubey ◽  
Shabbir Syed-Abdul ◽  
Joseph R. Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Growth Factors ◽  
Articular Cartilage ◽  
Current Status ◽  
Self Healing ◽  
Mechanical Stimuli ◽  
Stem Cell Therapies ◽  
Differentiation Potential ◽  
Cell Therapies

Knee osteoarthritis (OA) is a chronic degenerative disorder which could be distinguished by erosion of articular cartilage, pain, stiffness, and crepitus. Not only aging-associated alterations but also the metabolic factors such as hyperglycemia, dyslipidemia, and obesity affect articular tissues and may initiate or exacerbate the OA. The poor self-healing ability of articular cartilage due to limited regeneration in chondrocytes further adversely affects the osteoarthritic microenvironment. Traditional and current surgical treatment procedures for OA are limited and incapable to reverse the damage of articular cartilage. To overcome these limitations, cell-based therapies are currently being employed to repair and regenerate the structure and function of articular tissues. These therapies not only depend upon source and type of stem cells but also on environmental conditions, growth factors, and chemical and mechanical stimuli. Recently, the pluripotent and various multipotent mesenchymal stem cells have been employed for OA therapy, due to their differentiation potential towards chondrogenic lineage. Additionally, the stem cells have also been supplemented with growth factors to achieve higher healing response in osteoarthritic cartilage. In this review, we summarized the current status of stem cell therapies in OA pathophysiology and also highlighted the potential areas of further research needed in regenerative medicine.

scholarly journals The Safety and Efficiency of Addressing ARDS Using Stem Cell Therapies in Clinical Trials

2019 ◽  
pp. 219-238 ◽  
Author(s):  
Emanuele Rezoagli ◽  
Emma J. Murphy ◽  
John Laffey ◽  
Daniel O’Toole
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Stem Cell Therapies ◽  
Cell Therapies
Sign in / Sign up

Export Citation Format

Share Document